The goal of the Biostatistics Shared Sen/ice (BSS) is to provide basic, translational, clinical, and epidemiology investigators at the University of Maryland Mariene and Stewart Greenebaum Cancer Center (UMGCC) with access to quality statistical science. Functions ofthe shared service include designing, reviewing, and monitoring protocols;statistical analysis, planning, and reporting;designing and analyzing high dimensional data, including microarray gene expression, single nucleotide polymorphisms (SNPs), epigenetics, proteomics;preparing grant applications and manuscripts;providing biostatistics training and advice on clinical data management;and database computing. BSS also provides investigators at UMGCC with advanced statistical methods and expertise developed under other grants funded by the National Cancer Institute, such as design and analysis of combination studies, analysis of microarray and cancer epidemiology data, and SNP data mining. Statisticians in this shared service collaborate with investigators in all five cancer programs at UMGCC: Experimental Therapeutics, Hormone Responsive Cancers, Molecular and Structural Biology, Tumor Immunology and Immunotherapy, and Viral Oncology. The shared service has access to excellent computing resources and statistical software packages (e.g., SAS, StatXact, Splus, Matlab, nQuery), database management software (e.g.. Access, Oncore?), and specialized statistical software necessary for efficient and effective support of UMGCC's programs. In calendar year 2009, BSS supported 145 research projects from 63 investigators and 60 grant applications, totaling 9,454 hours. Nearly 52 percent of total effort was spent on funded cancer projects. For this grant, we request 2.65 full-time equivalent (FTE) of biostatistics and bioinformatics support and 0.5 FTE of administrative and databaseassistance to provide biostatistics and statistical bioinformatics support to each cancer program at UMGCC.
; The Biostatistics Shared Service provides the critically needed study design, power analysis, data management, statistical/bioinformatics analysis and manuscript preparation support for all UMGCC programs.
|Appelt, Ane L; Vogelius, Ivan R; Pløen, John et al. (2014) Long-term results of a randomized trial in locally advanced rectal cancer: no benefit from adding a brachytherapy boost. Int J Radiat Oncol Biol Phys 90:110-8|
|Vogelius, Ivan R; Bentzen, Søren M (2014) Hypofractionated radiation therapy for prostate cancer: more food for thought from recent trial. J Clin Oncol 32:1852-3|
|Bao, Ting; Cai, Ling; Snyder, Claire et al. (2014) Patient-reported outcomes in women with breast cancer enrolled in a dual-center, double-blind, randomized controlled trial assessing the effect of acupuncture in reducing aromatase inhibitor-induced musculoskeletal symptoms. Cancer 120:381-9|
|Barnett, Gillian C; Thompson, Deborah; Fachal, Laura et al. (2014) A genome wide association study (GWAS) providing evidence of an association between common genetic variants and late radiotherapy toxicity. Radiother Oncol 111:178-85|
|Bentzen, S M; Yarnold, J (2014) A toast to the silver anniversary of Clinical Oncology: a quarter of a century of advances in evidence-based radiation dose fractionation. Clin Oncol (R Coll Radiol) 26:599-601|
|Håkansson, Katrin; Specht, Lena; Aznar, Marianne C et al. (2014) Prescribing and evaluating target dose in dose-painting treatment plans. Acta Oncol 53:1251-6|
|Due, Anne K; Vogelius, Ivan R; Aznar, Marianne C et al. (2014) Recurrences after intensity modulated radiotherapy for head and neck squamous cell carcinoma more likely to originate from regions with high baseline [18F]-FDG uptake. Radiother Oncol 111:360-5|
|Song, Xiaomeng; Xia, Ronghui; Li, Jiang et al. (2014) Common and complex Notch1 mutations in Chinese oral squamous cell carcinoma. Clin Cancer Res 20:701-10|
|Gojo, Ivana; Tan, Ming; Fang, Hong-Bin et al. (2013) Translational phase I trial of vorinostat (suberoylanilide hydroxamic acid) combined with cytarabine and etoposide in patients with relapsed, refractory, or high-risk acute myeloid leukemia. Clin Cancer Res 19:1838-51|
|Natarajan, Karthika; Xie, Yingqiu; Burcu, Mehmet et al. (2013) Pim-1 kinase phosphorylates and stabilizes 130 kDa FLT3 and promotes aberrant STAT5 signaling in acute myeloid leukemia with FLT3 internal tandem duplication. PLoS One 8:e74653|
Showing the most recent 10 out of 18 publications